Applications of Morpholin-4-Yl-Phenyl-Acetic Acid in Industrial Manufacturing

Morpholin-4-Yl-Phenyl-Acetic Acid serves specialized roles within pharmaceutical synthesis, agrochemical formulation, and fine chemical intermediates manufacturing. As a direct manufacturer, we support well-defined industrial segments that demand controlled quality, application-tailored specifications, and verified compliance. Below, we detail its established uses within core downstream sectors.

1. Non-Steroidal Anti-Inflammatory Drug (NSAID) Intermediate Production

Pharmaceutical manufacturers integrate this compound during the multi-step synthesis of certain NSAIDs. It provides a functionalized aromatic backbone that is critical for the targeted modification and structural optimization of anti-inflammatory agents. This step requires precise molar additions to achieve stringent impurity profiles and regulatory compliance demanded by drug master files.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP/NF Monographs
• EDQM CEP certification (where required)
• FDA 21 CFR Part 211 (US Drug cGMPs)

Typical usage ratio

• 0.8–1.2 molar equivalents relative to target API precursor; adjustments based on stoichiometry and impurity control

Downstream process integration

• Employed during amidation or acylation stage following halogenation or nitration; isolation step supports crystalline intermediate purification before subsequent derivatization

Final product types

• Bulk NSAID intermediates (e.g., building blocks for diclofenac and related derivatives)
• Final formulated NSAID active pharmaceutical ingredients

2. Selective Herbicide Active Ingredient Synthesis

Agrochemical formulators utilize this acid as a key intermediate in the construction of heterocyclic herbicide compounds. It supplies a morpholine ring that imparts target-specific phytotoxicity, enhancing crop safety and weed selectivity. The integration requires precise charge and compatibility with solvent systems to maintain green chemistry benchmarks and regional registration standards.

Industry compliance standards

• OECD Good Laboratory Practice (GLP) for Chemical Testing
• FAO/WHO Specification for Plant Protection Products
• ISO 9001:2015 Quality Management Systems
• REACH (EC No 1907/2006) registration for raw material traceability (EU market)

Typical usage ratio

• 0.7–1.1 parts by weight per 1 part of targeted triazine or benzoxazinone scaffold, modified per crop-specific registration requirements

Downstream process integration

• Incorporated at the nucleophilic substitution or cyclization stage during herbicide active ingredient assembly; followed by aqueous or organic extraction and formulation blending

Final product types

• Active herbicide ingredients for selective broadleaf or grass control
• Technical grade herbicide concentrates

3. Custom Peptide and Amino Acid Derivative Manufacturing

Manufacturers active in peptide synthesis employ this acid to introduce morpholine-amino acid hybrid motifs for research reagents and specialty pharmaceuticals. The input supports both solution and solid-phase peptide synthesis workflows, contributing customized properties such as enhanced solubility or protease resistance. Quality oversight is aligned with bioanalytical purity and batch-to-batch performance validation.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• Ph. Eur. General Texts 2034 for Peptides
• ISO 13485:2016 for Medical Device Ingredients if used in in vitro diagnostics
• USP <1045> Biotechnology-Derived Articles

Typical usage ratio

• 0.05–0.2 molar ratio as a protected or activated amino acid extender within peptide chain elongation, adjusted according to peptide sequence design

Downstream process integration

• Integrated during Fmoc or Boc protection protocols, or used as a building block in liquid-phase assembly; finalized by preparative HPLC for purity isolation

Final product types

• Synthesized peptide chains with morpholinyl-amino acid residues
• Custom amino acid surrogates used in pharmaceutical research

4. Specialty Intermediate for Fluorescence Tag Synthesis

Producers of chemical probes and bioconjugates utilize this acid to introduce rigid, electron-donating substituents into aromatic scaffolds, optimizing the spectral properties of fluorescent tags. The material’s input impacts quantum yield and photostability outcomes in final probes, especially where pH-sensitive applications demand both chemical stability and controlled reactivity during linker coupling steps.

Industry compliance standards

• ISO 17034:2016 Reference Material Production
• RoHS Directive 2011/65/EU for chemical probe components (electronics applications)
• GMP-like quality control procedures for diagnostic reagent intermediates
• Analytical validation according to ICH Q6A Specifications (Test Procedures)

Typical usage ratio

• Variable (0.01–0.08 molar equivalents), adjusted according to desired probe sensitivity and labeling efficiency during tag assembly

Downstream process integration

• Engaged at stepwise aromatic substitution, then purified via column chromatography before conjugation to reporter groups or biomolecules

Final product types

• High-sensitivity fluorescent tags for biochemical assays
• Custom molecular probes for diagnostics and imaging

5. Intermediate for CNS-Active Small Molecule Synthesis

Specialty pharmaceutical ingredient producers apply this acid as a ring-structural element in advanced intermediates for CNS medicinal chemistry projects. Its inclusion helps tune lipophilicity and receptor binding in neuroactive small molecules, supporting flexibility in design for nootropic and anxiolytic APIs. Process control focuses on highly selective coupling and chain extension stages to prevent unwanted side-reactivity and achieve the desired pharmacological activity.

Industry compliance standards

• ICH Q3A/B Impurity Control for Drug Substances
• WHO TRS 981 Annex 2 (Good Practices for Pharmaceutical Quality Control Laboratories)
• FDA Drug Master File (DMF) guidance
• GMP Annex 2 for starting materials in neuroscientific R&D

Typical usage ratio

• 0.1–0.3 molar equivalents per step, varying depending on drug target structure and specific substitution pattern

Downstream process integration

• Utilized in the arylation or amide bond-forming step, followed by chromatography and characterization via NMR and HPLC prior to API candidate stage

Final product types

• Active intermediates for nootropic drug candidates
• CNS bioactive pharmaceutical prototypes and reference standards